This is a preview of subscription content, log in via an institution to check access.
Data availability
The data that support the findings of this study are not openly available due to reasons of sensitivity and are available from the corresponding author upon reasonable request.
References
Tefferi A (2021) Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 96:145–162. https://doi.org/10.1002/ajh.26050
Campbell PJ, Green AR (2006) The myeloproliferative disorders. N Engl J Med 355:2452–2466. https://doi.org/10.1056/NEJMra063728
Alexander MP, Nasr SH, Kurtin PJ, Casey ET, Hernandez LP, Fidler ME, Sethi S, Cornell LD (2015) Renal extramedullary hematopoiesis: interstitial and glomerular pathology. Mod Pathol 28:1574–1583. https://doi.org/10.1038/modpathol.2015.117
Said SM, Leung N, Sethi S, Cornell LD, Fidler ME, Grande JP, Herrmann S, Tefferi A, D’Agati VD, Nasr SH (2011) Myeloproliferative neoplasms cause glomerulopathy. Kidney Int 80:753–759. https://doi.org/10.1038/ki.2011.147
Au WY, Chan KW, Lui SL, Lam CC, Kwong YL (1999) Focal segmental glomerulosclerosis and mesangial sclerosis associated with myeloproliferative disorders. Am J Kidney Dis 34:889–893. https://doi.org/10.1016/S0272-6386(99)70047-8
Büttner-Herold M, Sticht C, Wiech T, Porubsky S (2021) Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms. Histopathology 78:738–748. https://doi.org/10.1111/his.14282
Floege J, Eitner F, Alpers CE (2008) A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol 19:12–23. https://doi.org/10.1681/ASN.2007050532
Lee HS, Song CY (2010) Effects of TGF-beta on podocyte growth and disease progression in proliferative podocytopathies. Kidney Blood Press Res 33:24–29. https://doi.org/10.1159/000285844
Schiffer M, Bitzer M, Roberts IS, Kopp JB, ten Dijke P, Mundel P, Böttinger EP (2001) Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 108:807–816. https://doi.org/10.1172/JCI12367
Funding
None to declare.
Author information
Authors and Affiliations
Contributions
HJK was responsible for acquisition, and wrote the main manuscript; MJ and BJL prepared figures; JWC was responsible for patient care; SHH is the principal investigator and was involved in all aspects of patient care, data collection and manuscript preparation. All authors reviewed the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interests.
Ethical approval
All the procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional committee and with the 1964 Helsinki Declaration and its later amendments.
Human and animal rights
All the procedures performed in the study were in accordance with the ethical standards of the institutional review board and with the 1964 Helsinki Declaration and its later amendments.
Informed consent
The participant was provided informed consent prior to their participation.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Kim, H.J., Jung, M., Lim, B.J. et al. Primary myelofibrosis-related glomerulopathy with renal extramedullary hematopoiesis. J Nephrol 36, 2387–2390 (2023). https://doi.org/10.1007/s40620-023-01621-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40620-023-01621-z